BBNX
Beta Bionics, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth n/a ·
share flow n/a ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.90M | New | $47.35M | 0.0% | New | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 946.35K | New | $11.58M | 0.0% | New | 1 | SEC ↗ ×2 |
| 3 | Marshall Wace ✦ | 673.66K | New | $8.25M | 0.0% | New | 1 | SEC ↗ ×3 |
| 4 | T. Rowe Price ✦ | 636.20K | New | $7.79M | 0.0% | New | 1 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 364.33K | New | $4.46M | 0.0% | New | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 306.02K | New | $3.75M | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 105.97K | New | $1.30M | 0.0% | New | 1 | SEC ↗ |
| 8 | Soros Fund Management ✦ | 25.97K | New | $317,848 | 0.0% | New | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 20.75K | New | $253,992 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $47.35M | 0.0% |
| Citadel Advisors | $11.58M | 0.0% |
| Marshall Wace | $8.25M | 0.0% |
| T. Rowe Price | $7.79M | 0.0% |
| Point72 Asset Management | $4.46M | 0.0% |
| Geode Capital Management | $3.75M | 0.0% |
| State Street Global Advisors | $1.30M | 0.0% |
| Soros Fund Management | $317,848 | 0.0% |
| Two Sigma Investments | $253,992 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 129 holders, 49.02M shares, $491.50M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 775 sh · $13,446
Officer · 370 sh · $7,015
Director · 6.43K sh · $147,890
Officer · 2.65K sh · $58,300
Officer · 30.78K sh · $619,640
Officer · 775 sh · $12,028
Officer · 36.87K sh · $680,723
Officer, Director · 5.64K sh · $113,259
Officer · 5.33K sh · $101,815
Officer · 4.22K sh · $80,676
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology